4 results match your criteria: "National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory[Affiliation]"
CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Cytokine
October 2013
National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, P.O. Box 19643, Springfield, IL 62794-9643, USA; Department of Neurology, SouthernIllinois University School of Medicine, P.O. Box 19643, Springfield, IL 62794-9643, USA. Electronic address:
Identifying and blocking chemokine inflammatory mediators in pediatric opsoclonus-myoclonus syndrome (OMS) is critical to the treatment of this autoimmune, paraneoplastic, neurological disorder. In a prospective, case-control, clinico-scientific study of children with OMS compared to non-inflammatory neurological controls and other inflammatory neurological disorders, CCL19 (n=369) and CCL21 (n=312) were quantified in CSF and serum, respectively, by ELISA. Both cross-sectional and longitudinal effects of OMS and various immunotherapies were evaluated.
View Article and Find Full Text PDFPediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay.
J Interferon Cytokine Res
September 2013
National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Department of Neurology, Southern Illinois University School of Medicine, P.O. Box 19643, Springfield, IL 62794-9643, USA.
To define cytokine concentrations and detectability in children with noninflammatory neurological disorders (NIND). The multiplex bead assay technology was used for simultaneous measurement of 34 soluble cytokines/chemokines in cerebrospinal fluid (CSF) from 73 NIND. Sera from 36 healthy children and 37 NIND also were analyzed.
View Article and Find Full Text PDFExpression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.
Clin Exp Immunol
June 2013
Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Springfield, IL, USA.
Opsoclonus-myoclonus syndrome (OMS) is a neuroinflammatory disorder associated with remote cancer. To understand more clearly the role of inflammatory mediators, the concentration of CXCR3 ligands CXCL10, CXCL9 and CXCL11 was measured in 245 children with OMS and 81 paediatric controls using enzyme-linked immunosorbent assay (ELISA), and CXCR3 expression on CD4(+) T cells was measured by flow cytometry. Mean cerebrospinal fluid (CSF) CXCL10 was 2·7-fold higher in untreated OMS than controls.
View Article and Find Full Text PDFCytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders.
J Neurol Sci
March 2013
National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Department of Neurology, Southern Illinois University School of Medicine, USA.
Objective: To test for hypothesized disease- and treatment-induced changes in cytokines and adhesion molecules in children with opsoclonus-myoclonus syndrome (OMS).
Methods: Multiplex bead assay technology was used for simultaneous measurement of 34 soluble cytokines in cerebrospinal fluid (CSF) and serum. Soluble intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) were measured by ELISA.